Navigation Links
Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis
Date:10/15/2007

ogress to cause severe disability. Relapsing-remitting MS is the most common form of this disease.

According to the National Multiple Sclerosis Society, approximately 400,000 Americans acknowledge having MS, and every week about 200 people are diagnosed. Worldwide, multiple sclerosis may affect 2.5 million individuals.

About Alemtuzumab

Alemtuzumab is licensed in the United States as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL), and outside of the U.S. for the treatment of B-CLL in patients who have been treated with alkylating agents and who have failed fludarabine therapy. The product was launched in its oncology indication in 2001 in the US, where it is marketed by Bayer HealthCare Pharmaceuticals Inc. as Campath(R), and in Europe, where it is named MabCampath(R).

Alemtuzumab is a humanized monoclonal antibody that binds to a specific target, CD52, on cell surfaces and directs the body's immune system to destroy those cells. It is the first and only monoclonal antibody approved by the FDA for the treatment of patients with B-CLL.

Genzyme and Bayer Schering Pharma AG, Germany are co-developing alemtuzumab in oncology, multiple sclerosis and other indications. Bayer Schering Pharma AG, Germany holds exclusive worldwide marketing and distribution rights to alemtuzumab.

Campath has a boxed warning which includes information on cytopenias, infusion reactions, and infections. The most commonly reported adverse reactions in patients with B-CLL were infusion reactions (fever, chills, hypotension, urticaria, nausea, rash, tachycardia, dyspnea), cytopenias (neutropenia, lymphopenia, thrombocytopenia, anemia), and infections (CMV viremia, CMV infection, other infections). In clinical trials, the frequency of infusion reactions was highest in the first week of treatment. Other commonly reported adverse reactions include vomiting, abdominal pain, insomnia and anxiety. The most commonly reported serious adv
'/>"/>

SOURCE Genzyme Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
2. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
3. Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line Results with ...
4. Evotec Reports Positive Proof-of-Concept Top-Line Results with Insomnia Drug Candidate EVT 201
5. Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
6. Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Companys Investigational Drug to Treat Cocaine and Methamphetamine Addiction
7. Cobalis Expects to Report Phase III Top-Line Results in May
8. XenoPort Reports Positive Top-Line Phase 3 Trial Results of XP13512 in Restless Legs Syndrome
9. Amarin Reports Top-Line Results of two Phase III Studies of Miraxion in Huntingtons Disease
10. UCB Announces Positive Top-Line Phase III Results for Keppra as Adjunctive Therapy for Partial Onset Seizures in Paediatric Patients from One Month to Less than Four Years of Age
11. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Dose Escalation Trial with Tovaxin for Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... -- Stryker brand ambassadors Fred Funk and Hal ... Tour event near Minneapolis, MN , which begins ... Stryker is the official joint replacement products company of the PGA ... st through Sunday, August 3 rd , fans will be ... destination located in the Pioneer Press Expo tent located near the ...
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron ... (EURONEXT: SAN and NYSE: SNY ) today ... alirocumab in people with hypercholesterolemia met their primary efficacy ... low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared to ... antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... and SAN DIEGO , July ... ARNA ) announced today that an article based ... of lorcaserin entitled, "Early Weight Loss While on Lorcaserin, Diet, ... was recently published in the online issue of Obesity ... The objective of these analyses was to identify whether there ...
Breaking Medicine Technology:Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 2Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 3Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 4Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7
... Mylan Inc. (Nasdaq: MYL ) today announced that it has ... amount of 7.625% Senior Notes due 2017 and $700 million ... is using $1.0 billion of the net proceeds from ... loans, thereby reducing senior secured leverage and extending the maturity profile ...
... SHENZHEN, China , May 19 /PRNewswire-Asia/ ... Medical" or the "Company"), a leading manufacturer of,medical dressings, ... consumer products industries, announced today that in,connection with the ... common stock, par value $0.001 per share, ...
Cached Medicine Technology:Mylan Announces Completion of Senior Notes Offering 2Winner Medical Group Inc. Announces Exercise of Over-Allotment Option Bringing Aggregate Net Proceeds of the Public Offering to $8.8 Million 2Winner Medical Group Inc. Announces Exercise of Over-Allotment Option Bringing Aggregate Net Proceeds of the Public Offering to $8.8 Million 3Winner Medical Group Inc. Announces Exercise of Over-Allotment Option Bringing Aggregate Net Proceeds of the Public Offering to $8.8 Million 4
(Date:7/30/2014)... Amy Norton HealthDay Reporter ... time in a garden might help soothe the agitation that ... Looking at 17 past studies, British researchers found evidence that ... help soothe some dementia patients, anxiety. The study authors ... a tough subject to study -- and the evidence of ...
(Date:7/30/2014)... Of the many sub-groups of cells jockeying for ... not be those that can proliferate the fastest, researchers ... in an advance online publication of the journal ... the treatment of cancer with precision medicines, the study ... are truly driving the tumor,s growth and metastasis and ...
(Date:7/30/2014)... July 30, 2014 According to ... Machine Vision Market by Technology (ICS, MES, ERP, ... Components (Camera, FGOL), Application (Process, Discrete) - Global ... by MarketsandMarkets, the Mexican market is expected to ... by 2020. , Browse 70 market data Tables ...
(Date:7/30/2014)... July 30, 2014 Everyone knows that the ... basically everyone. Whether people are looking for something to buy, ... a dentist, the internet is pretty much always going to ... Dental in Lauderdale Florida is so happy to announce the ... web presence into the modern age. Whether a person wants ...
(Date:7/30/2014)... 2014 Shabaikai is an ambitious historical ... the Pomo Indians located on the shores of Russian ... Shabaikai, meaning ‘crooked snake’. Clarkson takes the reader into ... violence of prohibition and organized crime, providing a glimpse ... the most powerful men in the world convene the ...
Breaking Medicine News(10 mins):Health News:Gardens a Center of Calm for People With Dementia 2Health News:Gardens a Center of Calm for People With Dementia 3Health News:Target growth-driving cells within tumors, not fastest-proliferating cells 2Health News:Target growth-driving cells within tumors, not fastest-proliferating cells 3Health News:Mexico Factory Automation and Machine Vision Market Worth $6.99 Billion by 2020 - New Report by MarketsandMarkets 2Health News:Mexico Factory Automation and Machine Vision Market Worth $6.99 Billion by 2020 - New Report by MarketsandMarkets 3Health News:Mexico Factory Automation and Machine Vision Market Worth $6.99 Billion by 2020 - New Report by MarketsandMarkets 4Health News:Sierra Dental Releases New Website For Fort Lauderdale Residents 2Health News:Bill E. Clarkson Releases Debut Fact-Based Novel, Shabaikai 2
... Clemson University researcher Julia Frugoli has received $132,769 as ... from the National Science Foundation to continue her study ... other to control their growth and development. The ... College of Agriculture, Forestry & Life Sciences, genetics and ...
... , MONDAY, May 14 (HealthDay News) -- In black ... arteries in the eye,s retina (retinal arteriolar narrowing) is ... study finds. , "Retinal arteriolar narrowing has long been ... hypertension [high blood pressure] and cardiovascular disease," Dr. Monique ...
... Philadelphia, PA, May 14, 2012 Health professionals commonly say, ... but is there any scientific basis for the advice? ... your past experience with needle pricks, along with information you ... is published in the May issue of Pain . ...
... A new type of artificial eye system could one day ... to degenerative eye diseases such as macular degeneration, according to ... tiny solar panel-like cells that are surgically placed beneath the ... with a miniature camera, and a pocket PC that processes ...
... examining the effects of resveratrol on individuals with mild ... as more than two dozen academic institutions recruit volunteers ... Ph.D., director of Georgetown University Medical Center,s Memory Disorders ... Resveratrol is a compound found in red grapes, ...
... (HealthDay News) -- Doing more repetitions with less weight ... training with heavy weights, a new Canadian study indicates. ... yourself to the point of fatigue, according to the ... examined how different combinations of weight loads and repetitions ...
Cached Medicine News:Health News:Clemson professor awarded nearly $600,000 4-year grant to study language of plants 2Health News:To avoid pain during an injection, look away 2Health News:In Rat Study, Eye Device Shows Promise for Restoring Sight 2Health News:Georgetown physician leads national resveratrol study for Alzheimer's disease 2Health News:Georgetown physician leads national resveratrol study for Alzheimer's disease 3Health News:With Weights, You Can Lighten Your Load 2
... PreVue B. Burgdorferi Antibody Detection Assay is ... the qualitative presumptive (first step) detection of ... in human serum or whole blood. Rapid ... accuracy make the Wampole PreVue B. burgdorferi ...
... to U.S. and international engineering and ... Screw and Plating System* provides seamless ... of use for open reduction internal ... TC-100 system works well beyond the ...
Comprehensive range of integrated implants and instruments including - Basic, Small, Mini, Pelvic and Foot Sets....
... international engineering and design specifications, Smith ... System* provides seamless integration with existing ... open reduction internal fixational procedures (AO ... well beyond the standard, providing a ...
Medicine Products: